Compare
Unicycive Therapeutics, Inc. vs NextCure, Inc. vs Atossa Therapeutics, Inc. vs Verrica Pharmaceuticals Inc.
| Latest fiscal year | Unicycive Therapeutics, Inc. UNCY | NextCure, Inc. NXTC | Atossa Therapeutics, Inc. ATOS | Verrica Pharmaceuticals Inc. VRCA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $35.58M |
| Revenue growth (YoY) | n/a | n/a | n/a | +370.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -34.2% |
| Net margin | n/a | n/a | n/a | -50.3% |
| Net income | -$26.55M | -$55.84M | -$34.77M | -$17.89M |
| EPS (Diluted) | -$1.67 | -$19.65 | -$4.04 | -$1.68 |
| Operating cash flow | -$31.32M | -$49.61M | -$29.76M | -$17.63M |
| Free cash flow | -$31.34M | n/a | -$29.79M | -$17.63M |
| Cash & equivalents | $29.20M | $25.98M | $41.30M | $30.15M |
| Total assets | $49.13M | $50.18M | $47.61M | $47.13M |
| Total liabilities | $18.94M | $15.24M | $8.26M | $22.39M |
| Shareholders' equity | $30.20M | $34.94M | $39.35M | $24.74M |
| Return on year-end equity | -87.9% | -159.8% | -88.4% | -72.3% |
| Shares outstanding | 22.11M | 3.51M | 8.61M | 17.18M |
Revenue, most recent five fiscal years
| Fiscal year | Unicycive Therapeutics, Inc. | NextCure, Inc. | Atossa Therapeutics, Inc. | Verrica Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $675.0K Ended 2023-12-31 | $22.38M Ended 2020-12-31 | $1.8K Ended 2015-12-31 | $35.58M Ended 2025-12-31 |
| 1 year earlier | $951.0K Ended 2022-12-31 | $6.35M Ended 2019-12-31 | $40.1K Ended 2014-12-31 | $7.57M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $632.6K Ended 2013-12-31 | $5.12M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $481.8K Ended 2012-12-31 | $9.03M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.5K Ended 2011-12-31 | $12.00M Ended 2021-12-31 |